China’s radiopharmaceuticals on expressway: 2014–2021
Abstract This review provides an essential overview on the progress of rapidly-developing China’s radiopharmaceuticals in recent years (2014–2021). Our discussion reflects on efforts to develop potential, preclinical, and in-clinical radiopharmaceuticals including the following areas: (1) brain imaging agents, (2) cardiovascular imaging agents, (3) infection and inflammation imaging agents, (4) tumor radiopharmaceuticals, and (5) boron delivery agents (a class of radiopharmaceutical prodrug) for neutron capture therapy. Especially, the progress in basic research, including new radiolabeling methodology, is highlighted from a standpoint of radiopharmaceutical chemistry. Meanwhile, we briefly reflect on the recent major events related to radiopharmaceuticals along with the distribution of major R&D forces (universities, institutions, facilities, and companies), clinical study status, and national regulatory supports. We conclude with a brief commentary on remaining limitations and emerging opportunities for China’s radiopharmaceuticals..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:110 |
|---|---|
| Enthalten in: |
Radiochimica acta - 110(2022), 6-9 vom: 21. Apr., Seite 765-784 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cui, Xi-Yang [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 Walter de Gruyter GmbH, Berlin/Boston |
|---|
| doi: |
10.1515/ract-2021-1137 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2143269439 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2143269439 | ||
| 003 | DE-627 | ||
| 005 | 20240308141311.0 | ||
| 007 | tu | ||
| 008 | 230813s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1515/ract-2021-1137 |2 doi | |
| 035 | |a (DE-627)OLC2143269439 | ||
| 035 | |a (DE-B1597)ract-2021-1137-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q VZ |
| 082 | 0 | 4 | |a 540 |a 610 |q VZ |
| 084 | |a 35.15 |2 bkl | ||
| 100 | 1 | |a Cui, Xi-Yang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a China’s radiopharmaceuticals on expressway: 2014–2021 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © 2022 Walter de Gruyter GmbH, Berlin/Boston | ||
| 520 | |a Abstract This review provides an essential overview on the progress of rapidly-developing China’s radiopharmaceuticals in recent years (2014–2021). Our discussion reflects on efforts to develop potential, preclinical, and in-clinical radiopharmaceuticals including the following areas: (1) brain imaging agents, (2) cardiovascular imaging agents, (3) infection and inflammation imaging agents, (4) tumor radiopharmaceuticals, and (5) boron delivery agents (a class of radiopharmaceutical prodrug) for neutron capture therapy. Especially, the progress in basic research, including new radiolabeling methodology, is highlighted from a standpoint of radiopharmaceutical chemistry. Meanwhile, we briefly reflect on the recent major events related to radiopharmaceuticals along with the distribution of major R&D forces (universities, institutions, facilities, and companies), clinical study status, and national regulatory supports. We conclude with a brief commentary on remaining limitations and emerging opportunities for China’s radiopharmaceuticals. | ||
| 700 | 1 | |a Liu, Yu |4 aut | |
| 700 | 1 | |a Wang, Changlun |4 aut | |
| 700 | 1 | |a Wen, Zihao |4 aut | |
| 700 | 1 | |a Li, Yichen |4 aut | |
| 700 | 1 | |a Tang, Haocheng |4 aut | |
| 700 | 1 | |a Diwu, Juan |4 aut | |
| 700 | 1 | |a Yang, Yuchuan |4 aut | |
| 700 | 1 | |a Cui, Mengchao |4 aut | |
| 700 | 1 | |a Liu, Zhibo |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Radiochimica acta |d De Gruyter, 1962 |g 110(2022), 6-9 vom: 21. Apr., Seite 765-784 |w (DE-627)129058785 |w (DE-600)104-1 |w (DE-576)014382628 |x 0033-8230 |7 nnns |
| 773 | 1 | 8 | |g volume:110 |g year:2022 |g number:6-9 |g day:21 |g month:04 |g pages:765-784 |
| 856 | 4 | 1 | |u https://doi.org/10.1515/ract-2021-1137 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-CHE | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4277 | ||
| 912 | |a GBV_ILN_4307 | ||
| 936 | b | k | |a 35.15 |j Radiochemie |j Radiochemie |q VZ |
| 951 | |a AR | ||
| 952 | |d 110 |j 2022 |e 6-9 |b 21 |c 04 |h 765-784 | ||